Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Terns Pharmaceuticals (Nasdaq: TERN) has announced the pricing of its upsized public offering, aiming to raise approximately $150.15 million. The offering includes 11,919,048 shares of common stock at $10.50 per share and 2,380,952 pre-funded warrants at $10.4999 each. Underwriters have a 30-day option to purchase up to 2,145,000 additional shares. The offering is expected to close on September 12, 2024.
Terns plans to use the proceeds to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, TERN-601, and other programs in the TERN-800 series. The funds will also support working capital and general corporate purposes. Jefferies and TD Cowen are leading the offering, with BMO Capital Markets and UBS Investment Bank as bookrunners.
Terns Pharmaceuticals (Nasdaq: TERN) ha annunciato il prezzo della sua offerta pubblica ampliata, con l’obiettivo di raccogliere circa $150,15 milioni. L’offerta comprende 11.919.048 azioni di azioni ordinarie a $10,50 per azione e 2.380.952 warrant prefinanziati a $10,4999 ciascuno. I sottoscrittori hanno un’opzione di 30 giorni per acquistare fino a 2.145.000 azioni aggiuntive. Si prevede che l’offerta si chiuda il 12 settembre 2024.
Terns prevede di utilizzare il ricavato per finanziare la ricerca, i trial clinici, lo sviluppo e la produzione dei principali candidati di prodotto, inclusi TERN-701, TERN-601 e altri programmi nella serie TERN-800. I fondi supporteranno anche il capitale di lavoro e scopi aziendali generali. Jefferies e TD Cowen stanno guidando l’offerta, con BMO Capital Markets e UBS Investment Bank come bookrunners.
Terns Pharmaceuticals (Nasdaq: TERN) ha anunciado el precio de su oferta pública ampliada, con el objetivo de recaudar aproximadamente $150,15 millones. La oferta incluye 11.919.048 acciones de acciones comunes a $10,50 por acción y 2.380.952 warrants prefinanciados a $10,4999 cada uno. Los suscriptores tienen una opción de 30 días para comprar hasta 2.145.000 acciones adicionales. Se espera que la oferta cierre el 12 de septiembre de 2024.
Terns planea utilizar los ingresos para financiar la investigación, ensayos clínicos, desarrollo y fabricación de candidatos clave, incluidos TERN-701, TERN-601 y otros programas en la serie TERN-800. Los fondos también apoyarán el capital de trabajo y propósitos corporativos generales. Jefferies y TD Cowen lideran la oferta, con BMO Capital Markets y UBS Investment Bank como bookrunners.
Terns Pharmaceuticals (Nasdaq: TERN)가 약 $150.15 백만을 모금하기 위한 증권 공개 매각 가격을 발표했습니다. 이번 세일에는 11,919,048 주식의 보통주가 주당 $10.50에 포함되며, 2,380,952 개의 사전 자금 조달 워런트가 각 $10.4999에 포함됩니다. 인수자들은 최대 2,145,000 추가 주식을 구매할 수 있는 30일 옵션을 가지고 있습니다. 이번 세일은 2024년 9월 12일에 종료될 것으로 예상됩니다.
Terns는 수익금을 사용해 주요 제품 후보인 TERN-701, TERN-601 및 TERN-800 시리즈의 기타 프로그램의 연구, 임상 시험, 개발 및 제조에 자금을 지원할 계획입니다. 이 자금은 또한 운영 자본과 일반 기업 목적을 지원합니다. Jefferies와 TD Cowen이 이 오퍼링을 주도하며, BMO Capital Markets와 UBS Investment Bank가 주관사로 참여합니다.
Terns Pharmaceuticals (Nasdaq: TERN) a annoncé le prix de son offre publique élargie, visant à lever environ $150,15 millions. L’offre comprend 11.919.048 actions ordinaires au prix de $10,50 par action et 2.380.952 bons de souscription préfinancés au prix de $10,4999 chacun. Les souscripteurs ont une option de 30 jours pour acheter jusqu’à 2.145.000 actions supplémentaires. La fermeture de l’offre est prévue pour le 12 septembre 2024.
Terns prévoit d’utiliser le produit de l’offre pour financer la recherche, les essais cliniques, le développement et la fabrication de candidats produits clés, y compris TERN-701, TERN-601 et d’autres programmes de la série TERN-800. Les fonds soutiendront également le fonds de roulement et des objectifs généraux de l’entreprise. Jefferies et TD Cowen dirigent l’offre, avec BMO Capital Markets et UBS Investment Bank comme chefs de file.
Terns Pharmaceuticals (Nasdaq: TERN) hat den Preis seiner erweiterten öffentlichen Angebot bekannt gegeben, mit dem Ziel, ungefähr $150,15 Millionen zu sammeln. Das Angebot umfasst 11.919.048 Aktien an Stammaktien zu einem Preis von $10,50 pro Aktie sowie 2.380.952 vorfinanzierte Optionsscheine zu einem Preis von $10,4999 pro Stück. Die Underwriter haben eine 30-tägige Option, um bis zu 2.145.000 zusätzliche Aktien zu erwerben. Der Abschluss des Angebots wird für den 12. September 2024 erwartet.
Terns plant, die Erlöse zur Finanzierung von Forschung, klinischen Studien, Entwicklung und Herstellung von Schlüsselprodukten zu verwenden, einschließlich TERN-701, TERN-601 und anderen Programmen der TERN-800-Serie. Die Mittel werden auch das Working Capital und allgemeine Unternehmenszwecke unterstützen. Jefferies und TD Cowen leiten das Angebot, während BMO Capital Markets und UBS Investment Bank als Hauptbuchführer fungieren.
Positive
- Upsized public offering to raise approximately $150.15 million
- Funds to be used for research, clinical trials, and development of key product candidates
- Strong underwriter support from major financial institutions
Negative
- Potential dilution of existing shareholders’ stake due to new share issuance
- Increased financial obligations and pressure to deliver results with the new funding
Terns Pharmaceuticals’ upsized $150.15 million public offering signifies strong investor interest and improved financial position. The pricing at $10.50 per share suggests market confidence in the company’s pipeline. This capital infusion will bolster Terns’ research and development efforts, particularly for key candidates like TERN-701 and TERN-601.
The inclusion of pre-funded warrants provides flexibility for certain investors and may indicate strategic positioning. With $150.15 million in gross proceeds, Terns significantly strengthens its balance sheet, potentially extending its operational runway. This funding could accelerate clinical trials and potentially bring products to market faster, enhancing long-term value for shareholders.
This substantial capital raise positions Terns Pharmaceuticals favorably in the competitive biotech landscape. The company’s focus on oncology and obesity aligns with high-demand therapeutic areas. The successful upsizing of the offering indicates strong market appetite for Terns’ potential.
Key to watch will be the progression of TERN-701 and TERN-601, as well as the TERN-800 series. This funding could accelerate their development, potentially leading to earlier value inflection points. However, investors should note that clinical success remains uncertain and the company will likely require additional funding rounds before reaching profitability, which is typical in biotech.
The timing of Terns’ offering is notable, coming amid volatile market conditions. The successful pricing above $10 per share and inclusion of warrants suggest a strategic approach to maximize capital raised while minimizing dilution. The 30-day option for underwriters to purchase additional shares could provide further upside.
Involvement of major underwriters like Jefferies and TD Cowen lends credibility to the offering. The diverse syndicate, including BMO Capital Markets and UBS Investment Bank, indicates broad institutional interest. This capital raise strengthens Terns’ position for potential partnerships or M&A activity, which could be catalysts for future value creation in the dynamic biotech sector.
FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $150.15 million, excluding any exercise of the underwriters’ option to purchase additional shares. Terns has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 12, 2024, subject to customary closing conditions. All of the securities are being offered by Terns.
Jefferies and TD Cowen are acting as lead book-running managers for the proposed offering. BMO Capital Markets and UBS Investment Bank are also acting as bookrunners for the proposed offering. Citizens JMP and Mizuho are acting as co-lead managers for the proposed offering.
Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufacturing of the Company’s key product candidates, including TERN-701, TERN-601 and other programs, including Terns’ TERN-800 series, and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 (File No. 333-269508) relating to the securities offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) on February 1, 2023 and declared effective on February 10, 2023. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement, final prospectus supplement, and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at prospectus_department@jefferies.com or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at 855-495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including the anticipated closing date of the proposed public offering and the Company’s anticipated use of proceeds of the proposed public offering. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023, and its prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
What is the size and price of Terns Pharmaceuticals’ (TERN) public offering?
Terns Pharmaceuticals (TERN) is offering 11,919,048 shares of common stock at $10.50 per share and 2,380,952 pre-funded warrants at $10.4999 each, aiming to raise approximately $150.15 million.
When is the expected closing date for Terns Pharmaceuticals’ (TERN) public offering?
The public offering for Terns Pharmaceuticals (TERN) is expected to close on September 12, 2024, subject to customary closing conditions.
How does Terns Pharmaceuticals (TERN) plan to use the proceeds from the public offering?
Terns Pharmaceuticals (TERN) intends to use the proceeds to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, TERN-601, and other programs in the TERN-800 series, as well as for working capital and general corporate purposes.
Who are the lead book-running managers for Terns Pharmaceuticals’ (TERN) public offering?
Jefferies and TD Cowen are acting as the lead book-running managers for Terns Pharmaceuticals’ (TERN) public offering.
